Related Experiment Video
Updated: Aug 16, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Treatment of adults with recurrent malignant glioma
1Department of Neurology, University of Alabama at Birmingham, 510 20 Street South, FOT 1020, Birmingham, AL, USA. bnabors@uab.edu
Abstract:
Virtually all malignant gliomas recur. Treatment options at recurrence have relied upon surgical intervention, radiation therapy or cytotoxic chemotherapy. Unfortunately, none are associated with significant improvements in survival. Advances in treatment options at recurrence have been dependent upon the combination of surgical resection, focal radiation and chemotherapy. Despite aggressive interventions, few patients have meaningful improvements. Current research focuses on novel targeted molecular therapy that will hopeful be able to take advantage of advances in our understanding of the biology of glial neoplasms.
Insights
Malignant gliomas frequently recur, and current treatments offer limited survival benefits. Future research is exploring targeted molecular therapies to improve outcomes for recurrent gliomas.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Malignant gliomas are aggressive brain tumors with a high rate of recurrence.
- Current treatment options for recurrent gliomas, including surgery, radiation, and chemotherapy, provide minimal survival improvements.
- There is a critical need for more effective therapeutic strategies for patients with recurrent malignant gliomas.
Purpose of the Study:
- To review the current landscape of treatment options for recurrent malignant gliomas.
- To highlight the limitations of existing therapies.
- To emphasize the potential of novel targeted molecular therapies in addressing the unmet needs in recurrent glioma treatment.
Main Methods:
- Literature review of studies on malignant glioma recurrence and treatment.
- Analysis of the efficacy of surgical intervention, radiation therapy, and cytotoxic chemotherapy.
- Exploration of emerging research in targeted molecular therapies for glial neoplasms.
Main Results:
- Recurrence is nearly universal in malignant gliomas.
- Standard treatment modalities at recurrence yield limited patient survival benefits.
- Advances have focused on combining existing therapies, yet significant improvements remain elusive.
Conclusions:
- Novel targeted molecular therapies hold promise for improving outcomes in recurrent malignant gliomas.
- Understanding the underlying biology of glial neoplasms is crucial for developing effective treatments.
- Future research directions are focused on personalized molecular approaches to combat glioma recurrence.
